tbuckley/cabot-search huggingface dataset:
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update
Authors: Marcus Maurer, Markus Magerl, Stephen Betschel, Werner Aberer, Ignacio J. Ansotegui, Emel Aygören‐Pürsün, Aleena Banerji, Noémi‐Anna Bara, Isabelle Boccon‐Gibod, Konrad Bork, Laurence Bouillet, Henrik Balle Boysen, Nicholas Brodszki, Paula J. Busse, Anette Bygum, Teresa Caballero, Mauro Cancian, Anthony Castaldo, Danny M. Cohn, Dorottya Csuka, Henriette Farkas, Mark Gompels, Richard Gower, Anete S. Grumach, Guillermo Guidos‐Fogelbach, Michihiro Hide, Hye‐Ryun Kang, Allen Phillip Kaplan, Constance Katelaris, Sorena Kiani‐Alikhan, Wei‐Te Lei, Richard Lockey, Hilary Longhurst, William R. Lumry, Andrew MacGinnitie, Alejandro Malbran, Inmaculada Martinez Saguer, Juan José Matta, Alexander Nast, Dinh Nguyen, Sandra A. Nieto‐Martinez, Ruby Pawankar, Jonathan Peter, Grzegorz Porebski, Nieves Prior, Avner Reshef, Marc Riedl, Bruce Ritchie, Farrukh Rafique Sheikh, William B. Smith, Peter J. Spaeth, Marcin Stobiecki, Elias Toubi, Lilian Agnes Varga, Karsten Weller, Andrea Zanichelli, Yuxiang Zhi, Bruce Zuraw, Timothy Craig
Journal: Allergy (2022)

Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast-feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.
Selective coronary arteriography
Authors: G. B. Lee
Journal: JAMA (1968)

Selective coronary arteriography has been developed during the past decade in an attempt to provide a visual display of the anatomical structure and pathological changes of the coronary arteries. Nonselective methods of coronary arteriography have failed in the past to show consistently the details of the coronary arterial tree. On the other hand, with improved selective methods, coronary arteriography has become a valuable adjunct in the diagnosis of coronary heart disease. It is now possible to arrive at a more precise diagnosis when the complete clinical evaluation is correlated with the objective findings of coronary arteriography. We feel that selective coronary studies are done best by a team composed of an internist and a roentgenologist. <h3>Technique</h3> Selective arteriography may be performed by various techniques, each with advantages and disadvantages. Since the technique of Sones has been widely publicized,<sup>1</sup>specific details will not be presented here. In contrast to the
World Flu Day: momentum from China for influenza control
Authors: None The Lancet
Journal: The Lancet (2018)

Nov 1 marks the first World Flu Day and was formally launched at the Asian-Pacific Centenary Spanish 1918-flu symposium in Shenzhen, China. The campaign was developed by George F Gao, director of the China Center for Disease Control and Prevention (CDC), in collaboration with other leading influenza specialists, including Yoshihiro Kawaoka from University of Wisconsin, WI, USA, Mark von Itzstein from Griffith University, QLD, Australia, and Kwok-Yung Yuen from Hong Kong University, Hong Kong. Gao told The Lancet that World Flu Day had four major purposes: to commemorate the centenary of the 1918–19 influenza pandemic; to raise public awareness of influenza; to accelerate scientific innovation and basic research efforts toward remaining challenges of influenza, particularly the development of a universal flu vaccine; and to push for stronger global political will in continuing the support of influenza prevention and control.
Genomic Differences by Race Emerge in Colorectal Cancer
Journal: Cancer Discovery (2021)

Black, white, and Asian/Pacific Islander patients with early-onset colorectal cancer have different patterns of nonsilent mutations than those diagnosed at a later age, researchers reported during the first week of the virtual American Association for Cancer Research Annual Meeting 2021. In addition, among those with early-onset cancer, Black patients had a significantly higher tumor mutation burden than white patients.
Leads from the MMWR. Measles--Dade County, Florida
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Herbicide Dermatitis
Authors: Malcolm C. Spencer
Journal: JAMA (1966)

A CONTACT DERMATITIS has been observed which may have such a striking clinical appearance that diagnosis is not dependent entirely upon distribution, but is tentatively made because of the violent tissue reaction. This is the acute contact dermatitis caused by the herbicide 2-chloro-N, N-diallylacetamide (Randox). <h3>Report of Cases</h3> A better understanding of dermatitis caused by this herbicide can be obtained by reviewing the history and findings in the following cases. <h3>Case 1.—</h3> A 35-year-old farmer was hospitalized because of marked violaceous discoloration of his severely swollen feet, associated with hemorrhagic bullae, crusting, and an exudative intertrigo (Figure). Similar but milder changes were present on the backs of his hands, pocket areas of each thigh, and buttocks. Values of routine laboratory studies (complete blood cell count [CBC] and urinalysis) were within limits of normal. His history confirmed the clinical diagnosis of dermatitis due to Randox. While planting corn three weeks ago
Therapeutic Escape in Gαq-mutant Uveal Melanoma: It's a FAK
Authors: J. William Harbour
Journal: Clinical Cancer Research (2021)

Abstract Through a synthetic lethal screen, ERK activation was found to mediate resistance to FAK inhibition in GNAQ-mutant uveal melanoma. With PLCB-PKC-ERK and Trio-FAK-Yap representing compensatory effectors of mutant Gαq signaling, combined inhibition of both pathways may be a promising therapeutic strategy in metastatic uveal melanoma. See related article by Paradis et al., p. 3190
Influence of Monitoring Strategy on Assessment of Ablation Success and Postablation Atrial Fibrillation Burden Assessment: Implications for Practice and Clinical Trial Design
Authors: Martin Aguilar, Laurent Macle, Marc W. Deyell, Robert Yao, Nathaniel M. Hawkins, Paul Khairy, Jason G. Andrade
Journal: Circulation (2021)

Various noninvasive intermittent rhythm monitoring strategies have been used to assess arrhythmia recurrences in trials evaluating pharmacological and invasive therapeutic interventions for atrial fibrillation (AF). We determined whether a frequency and duration of noninvasive rhythm monitoring could be identified that accurately detects arrhythmia recurrences and approximates the AF burden derived from continuous monitoring using an implantable cardiac monitor (ICM).The rhythm history of 346 patients enrolled in the CIRCA-DOSE trial (Cryoballoon Versus Contact-Force Irrigated Radiofrequency Catheter Ablation) was reconstructed. Using computer simulations, we evaluated event-free survival, sensitivity, negative predictive value, and AF burden of a range of noninvasive monitoring strategies, including those used in contemporary AF ablation trials.A total of 126 290 monitoring days were included in the analysis. At 12 months, 164 patients experienced atrial arrhythmia recurrence as documented by the ICM (1-year event-free survival, 52.6%). Most noninvasive monitoring strategies used in AF ablation trials had poor sensitivity for detecting arrhythmia recurrence. Sensitivity increased with the intensity of monitoring, with serial (3) short-duration monitors (24-/48-hour ECG monitors) missing a substantial proportion of recurrences (sensitivity, 15.8% [95% CI, 8.9%-20.7%] and 24.5% [95% CI, 16.2%-30.6%], respectively). Serial (3) longer-term monitors (14-day ECG monitors) more closely approximated the gold standard ICM (sensitivity, 64.6% [95% CI, 53.6%-74.3%]). AF burden derived from short-duration monitors significantly overestimated the true AF burden in patients with recurrences. Increasing monitoring duration resulted in improved correlation and concordance between noninvasive estimates of the invasive AF burden (R2 = 0.85 and interclass correlation coefficient = 0.91 for serial [3] 14-day ECG monitors versus ICM).The observed rate of postablation atrial tachyarrhythmia recurrence is highly dependent on the arrhythmia monitoring strategy employed. Between-trial discrepancies in outcomes may reflect different monitoring protocols. On the basis of measures of agreement, serial long-term (7-14 day) intermittent monitors accumulating at least 28 days of annual monitoring provide estimates of AF burden comparable with ICM. However, ICMs outperform intermittent monitoring for arrhythmia detection, and should be considered the gold standard for clinical trials. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01913522.
Abstract 290: Association Between Hourly Call Volume in Emergency Medical Dispatch Center and Dispatcher -Assisted Cardiopulmonary Resuscitation Instruction Time in Out-Of-Hospital Cardiac Arrest
Authors: Jong Hwan Kim, Tae Han Kim, Sang Do Shin, Ki Jeong Hong, Jeong Ho Park, Sun Young Lee, Jieun Pak
Journal: Circulation (2019)

Objectives: cardiac arrest recognition, ambulance dispatch and dispatcher assisted CPR by emergency medical dispatch (EMD) is crucial for good outcome of out-of-hospital cardiac arrest (OHCA).In EMD, crowding is caused by mismatch between numerous emergency calls and dispatchers per duty available Crowding in emergency department has been shown to decrease the performance and outcome, however little is known about effect of crowding in EMD. We aimed to evaluate incidence of crowding in emergency medical dispatch center and effect of emergency call crowding on dispatcher assisted CPR instruction performance in OHCA calls. Methods: We used nationwide OHCA database from 2013 to 2016, consisted of patients with presumed cardiac origin and dispatched by Seoul EMD. Main exposure was hourly number of total incoming emergency calls to EMD. Number of hourly calls were categorized into quartile (~4o calls, 41~51 calls, 52 ~61 calls and ~62 calls). Primary outcome was successful DA-CPR instruction provision within 120 seconds. Adjusted ratios (AORs) and 95% confidence intervals (CIs) were estimated to evaluate association between EMD crowding and outcome in multivariable logistic regression model. Results: Of a total of 12,722 patients, proportion of successful DA instruction were highest in least crowded quartile and lowest in the most crowded quartile (22.7% vs. 15.o% , p&lt;0.01). The adjusted odds ratios is 0.85 (95% CI 0.74 - 0.98) in most crowded EMD quartile with lesser proportion of DA instruction within 120 seconds. Crowding quartile 4 and quartile 3 was associated lesser favorable neurological outcome in multivariable logistic regression model.(adjusted OR(95% CI) 0.78 (0.60-0.99) and 0.70 (0.54- 0.91) respectively) . Conclusion: Crowding in emergency medicine dispatch caused by increased hourly call volume was associated with delayed dispatcher assisted CPR instruction provision. Medical directors might consider strategy approach to solve crowding in EMD according to crowding distribution.
METABOLOMIC PROFILE OF HUMAN MYOCARDIAL ISCHEMIA ASSESSED BY NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY OF PERIPHERAL BLOOD SERUM. A TRANSLATIONAL STUDY BASED ON TRANSIENT CORONARY OCCLUSION MODELS
Authors: Clara Bonanad, Vicente Bodi, Juan Sanchis, Jose M. Morales, Vannina G. Marrachelli, Julio Nunez, Maria J. Forteza, Fabian Chaustre, Cristina Gomez, Angel Llacer, Clara Bonanad
Journal: Journal of the American College of Cardiology (2012)
Global HIV Suppression Rates Fall Short of Targets
Authors: Bridget M. Kuehn
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
First-line treatment with immune checkpoint inhibitors (ICI) for metastatic gastric and esophagogastric junction (EGJ) adenocarcinoma in Latin America: Sociedad Latinoamericana de Gastroenterología Oncológica (SLAGO) evidence-based recommendations.
Authors: Maria Celeste Diaz, Adriana Della Valle, Consuelo Diaz, Guillermo Mendez, Juan Manuel O'Connor, Marcelo Garrido, Paola Catherine Montenegro, Renata D'Alpino Peixoto, Jorge Gallardo
Journal: Journal of Clinical Oncology (2022)

269 Background: Gastric and EGJ cancer in Latin America are associated with a high burden of disease and mortality. Treatment with combination chemotherapy (CT) is the current standard of care for metastatic disease, but with poor benefit. ICI appears as a new option in this setting improving survival and no local guidelines have been found addressing this issue. Methods: We carried out a comprehensive systematic review up to August 2021 and meta-analysis according to PRISMA guidelines and used the GRADE approach to summarize each question in evidence tables. Judgments regarding risk of bias, precision, consistency, directness, and likelihood of publication bias were made and categorized into 4 levels of evidence’s certainty ranging from very low to high. SLAGO formed a guideline panel composed of medical professionals from 6 countries in Latin America and prioritized 2 relevant questions. We provided de novo recommendations for the local setting using the Evidence-to-Decision (EtD) frameworks provided by GRADE to discuss benefits and harms, values and preferences, use of resources, feasibility, acceptability, and equity. Results: The panel agreed on 3 recommendations. For question 1, regarding the use of CT+ICI vs CT, the global certainty of evidence was rated as high. For question 2 (CT vs ICI), the global certainty of evidence was rated as low due to imprecision. The recommendation for question 1 was conditional for the use of CT+ICI among the population with CPS &gt; 1 and strong among those with CPS &gt; 5. For question 2, the recommendation was conditional against the treatment with ICI, regardless of CPS score. Concerns about the lack of economic evidence addressing the treatment's cost-effectiveness were identified. The panel highlighted the complexity of the Latin America health systems for the implementation of CT+ICI and its equity impact. Finally, some research priorities were highlighted (effectiveness in HER2+, CPS 1-4, or MSI-H tumours). Conclusions: The panel agreed on the net clinical benefit of CT+ICI for selected patients (CPS &gt; 5). Nonetheless, cost-effectiveness data are still lacking, especially in Latin America.
The Keys of the Kingdom
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron
Authors: Yu Gao, Curtis Cai, Alba Grifoni, Thomas R. Müller, Julia Niessl, Anna Olofsson, Marion Humbert, Lotta Hansson, Anders Österborg, Peter Bergman, Puran Chen, Annika Olsson, Johan K. Sandberg, Daniela Weiskopf, David A. Price, Hans-Gustaf Ljunggren, Annika C. Karlsson, Alessandro Sette, Soo Aleman, Marcus Buggert
Journal: Nature Medicine (2022)

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron (B.1.1.529) variant of concern (VOC) has destabilized global efforts to control the impact of coronavirus disease 2019 (COVID-19). Recent data have suggested that B.1.1.529 can readily infect people with naturally acquired or vaccine-induced immunity, facilitated in some cases by viral escape from antibodies that neutralize ancestral SARS-CoV-2. However, severe disease appears to be relatively uncommon in such individuals, highlighting a potential role for other components of the adaptive immune system. We report here that SARS-CoV-2 spike-specific CD4+ and CD8+ T cells induced by prior infection or BNT162b2 vaccination provide extensive immune coverage against B.1.1.529. The median relative frequencies of SARS-CoV-2 spike-specific CD4+ T cells that cross-recognized B.1.1.529 in previously infected or BNT162b2-vaccinated individuals were 84% and 91%, respectively, and the corresponding median relative frequencies for SARS-CoV-2 spike-specific CD8+ T cells were 70% and 92%, respectively. Pairwise comparisons across groups further revealed that SARS-CoV-2 spike-reactive CD4+ and CD8+ T cells were functionally and phenotypically similar in response to the ancestral strain or B.1.1.529. Collectively, our data indicate that established SARS-CoV-2 spike-specific CD4+ and CD8+ T cell responses, especially after BNT162b2 vaccination, remain largely intact against B.1.1.529. Peripheral ancestral SARS-CoV-2 spike-specific CD4+ and CD8+ T cells induced by BNT162b2 vaccination cross-react to the Omicron variant at higher levels than those induced by prior SARS-CoV-2 infection.
Insulin Administration
Journal: Diabetes Care (1990)

The injection of insulin is essential for management of type I diabetic patients and may be needed by type II diabetic patients for intermittent or continuous glycemic control. The species and dosage of insulin used should be consistent, and the patient's injection technique should be reviewed periodically with the diabetes-care team. The effective use of insulin to obtain the best metabolic control requires an understanding of the duration of action of the various types of insulin and the relationship of blood glucose levels to exercise, food intake, and stress; SMBG; and learning to adjust insulin dosage with the support and guidance of the diabetes-care team.
Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study
Authors: David M. O'Malley, Giovanni Mendonca Bariani, Philippe A. Cassier, Aurelien Marabelle, Aaron R. Hansen, Ana De Jesus Acosta, Wilson H. Miller, Tamar Safra, Antoine Italiano, Linda Mileshkin, Lei Xu, Fan Jin, Kevin Norwood, Michele Maio
Journal: Journal of Clinical Oncology (2022)

Pembrolizumab demonstrated durable antitumor activity in patients with previously treated, advanced microsatellite instability-high or mismatch repair-deficient (MSI-H/dMMR) tumors, including endometrial cancer, in the nonrandomized, open-label, multicohort, phase II KEYNOTE-158 study (NCT02628067). We report efficacy and safety outcomes for patients with MSI-H/dMMR endometrial cancer enrolled in KEYNOTE-158.Eligible patients from cohorts D (endometrial cancer, regardless of MSI-H/dMMR status) and K (any MSI-H/dMMR solid tumor, except colorectal) with previously treated, advanced MSI-H/dMMR endometrial cancer received pembrolizumab 200 mg once every 3 weeks for 35 cycles. The primary end point was objective response rate per RECIST version 1.1 by independent central radiologic review. Secondary end points included duration of response, progression-free survival, overall survival, and safety.As of October 5, 2020, 18 of 90 treated patients (20%) had completed 35 cycles of pembrolizumab and 52 (58%) had discontinued treatment. In the efficacy population (patients who received ≥ 1 dose of pembrolizumab and had ≥ 26 weeks of follow-up; N = 79), the median time from first dose to data cutoff was 42.6 (range, 6.4-56.1) months. The objective response rate was 48% (95% CI, 37 to 60), and median duration of response was not reached (2.9-49.7+ months). Median progression-free survival was 13.1 (95% CI, 4.3 to 34.4) months, and median overall survival was not reached (95% CI, 27.2 months to not reached). Among all treated patients, 76% had ≥ 1 treatment-related adverse event (grades 3-4, 12%). There were no fatal treatment-related events. Immune-mediated adverse events or infusion reactions occurred in 28% of patients (grades 3-4, 7%; no fatal events).Pembrolizumab demonstrated robust and durable antitumor activity and encouraging survival outcomes with manageable toxicity in patients with previously treated, advanced MSI-H/dMMR endometrial cancer.